356 related articles for article (PubMed ID: 27282351)
1. The oncocytic subtype is genetically distinct from other pancreatic intraductal papillary mucinous neoplasm subtypes.
Basturk O; Tan M; Bhanot U; Allen P; Adsay V; Scott SN; Shah R; Berger MF; Askan G; Dikoglu E; Jobanputra V; Wrzeszczynski KO; Sigel C; Iacobuzio-Donahue C; Klimstra DS
Mod Pathol; 2016 Sep; 29(9):1058-69. PubMed ID: 27282351
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological significance of somatic RNF43 mutation and aberrant expression of ring finger protein 43 in intraductal papillary mucinous neoplasms of the pancreas.
Sakamoto H; Kuboki Y; Hatori T; Yamamoto M; Sugiyama M; Shibata N; Shimizu K; Shiratori K; Furukawa T
Mod Pathol; 2015 Feb; 28(2):261-7. PubMed ID: 25081753
[TBL] [Abstract][Full Text] [Related]
3. KRAS/GNAS-testing by highly sensitive deep targeted next generation sequencing improves the endoscopic ultrasound-guided workup of suspected mucinous neoplasms of the pancreas.
Schmitz D; Kazdal D; Allgäuer M; Trunk M; Vornhusen S; Nahm AM; Doll M; Weingärtner S; Endris V; Penzel R; Kirchner M; Brandt R; Neumann O; Sültmann H; Budczies J; Kienle P; Magdeburg R; Hetjens S; Schirmacher P; Bergmann F; Rudi J; Stenzinger A; Volckmar AL
Genes Chromosomes Cancer; 2021 Jul; 60(7):489-497. PubMed ID: 33686791
[TBL] [Abstract][Full Text] [Related]
4. Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas.
Amato E; Molin MD; Mafficini A; Yu J; Malleo G; Rusev B; Fassan M; Antonello D; Sadakari Y; Castelli P; Zamboni G; Maitra A; Salvia R; Hruban RH; Bassi C; Capelli P; Lawlor RT; Goggins M; Scarpa A
J Pathol; 2014 Jul; 233(3):217-27. PubMed ID: 24604757
[TBL] [Abstract][Full Text] [Related]
5. Preoperative next-generation sequencing of pancreatic cyst fluid is highly accurate in cyst classification and detection of advanced neoplasia.
Singhi AD; McGrath K; Brand RE; Khalid A; Zeh HJ; Chennat JS; Fasanella KE; Papachristou GI; Slivka A; Bartlett DL; Dasyam AK; Hogg M; Lee KK; Marsh JW; Monaco SE; Ohori NP; Pingpank JF; Tsung A; Zureikat AH; Wald AI; Nikiforova MN
Gut; 2018 Dec; 67(12):2131-2141. PubMed ID: 28970292
[TBL] [Abstract][Full Text] [Related]
6. GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma.
Tan MC; Basturk O; Brannon AR; Bhanot U; Scott SN; Bouvier N; LaFemina J; Jarnagin WR; Berger MF; Klimstra D; Allen PJ
J Am Coll Surg; 2015 May; 220(5):845-854.e1. PubMed ID: 25840541
[TBL] [Abstract][Full Text] [Related]
7. Molecular and clinicopathological features of appendiceal mucinous neoplasms.
Yanai Y; Saito T; Hayashi T; Akazawa Y; Yatagai N; Tsuyama S; Tomita S; Hirai S; Ogura K; Matsumoto T; Wada R; Yao T
Virchows Arch; 2021 Mar; 478(3):413-426. PubMed ID: 32821969
[TBL] [Abstract][Full Text] [Related]
8. Clinical Impact of KRAS and GNAS Analysis Added to CEA and Cytology in Pancreatic Cystic Fluid Obtained by EUS-FNA.
Faias S; Duarte M; Albuquerque C; da Silva JP; Fonseca R; Roque R; Dias Pereira A; Chaves P; Cravo M
Dig Dis Sci; 2018 Sep; 63(9):2351-2361. PubMed ID: 29796909
[TBL] [Abstract][Full Text] [Related]
9. Intraductal Papillary Mucinous Neoplasms Arise From Multiple Independent Clones, Each With Distinct Mutations.
Fischer CG; Beleva Guthrie V; Braxton AM; Zheng L; Wang P; Song Q; Griffin JF; Chianchiano PE; Hosoda W; Niknafs N; Springer S; Dal Molin M; Masica D; Scharpf RB; Thompson ED; He J; Wolfgang CL; Hruban RH; Roberts NJ; Lennon AM; Jiao Y; Karchin R; Wood LD
Gastroenterology; 2019 Oct; 157(4):1123-1137.e22. PubMed ID: 31175866
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma.
Ideno N; Ohtsuka T; Matsunaga T; Kimura H; Watanabe Y; Tamura K; Aso T; Aishima S; Miyasaka Y; Ohuchida K; Ueda J; Takahata S; Oda Y; Mizumoto K; Tanaka M
Pancreas; 2015 Mar; 44(2):311-20. PubMed ID: 25479586
[TBL] [Abstract][Full Text] [Related]
11. GNAS sequencing identifies IPMN-specific mutations in a subgroup of diminutive pancreatic cysts referred to as "incipient IPMNs".
Matthaei H; Wu J; Dal Molin M; Shi C; Perner S; Kristiansen G; Lingohr P; Kalff JC; Wolfgang CL; Kinzler KW; Vogelstein B; Maitra A; Hruban RH
Am J Surg Pathol; 2014 Mar; 38(3):360-3. PubMed ID: 24525507
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic intraductal tubulopapillary neoplasm is genetically distinct from intraductal papillary mucinous neoplasm and ductal adenocarcinoma.
Basturk O; Berger MF; Yamaguchi H; Adsay V; Askan G; Bhanot UK; Zehir A; Carneiro F; Hong SM; Zamboni G; Dikoglu E; Jobanputra V; Wrzeszczynski KO; Balci S; Allen P; Ikari N; Takeuchi S; Akagawa H; Kanno A; Shimosegawa T; Morikawa T; Motoi F; Unno M; Higuchi R; Yamamoto M; Shimizu K; Furukawa T; Klimstra DS
Mod Pathol; 2017 Dec; 30(12):1760-1772. PubMed ID: 28776573
[TBL] [Abstract][Full Text] [Related]
13. Impact of next-generation sequencing on the clinical diagnosis of pancreatic cysts.
Jones M; Zheng Z; Wang J; Dudley J; Albanese E; Kadayifci A; Dias-Santagata D; Le L; Brugge WR; Fernandez-del Castillo C; Mino-Kenudson M; Iafrate AJ; Pitman MB
Gastrointest Endosc; 2016 Jan; 83(1):140-8. PubMed ID: 26253016
[TBL] [Abstract][Full Text] [Related]
14. The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant.
Yamaguchi H; Kuboki Y; Hatori T; Yamamoto M; Shimizu K; Shiratori K; Shibata N; Shimizu M; Furukawa T
J Pathol; 2013 Nov; 231(3):335-41. PubMed ID: 23893889
[TBL] [Abstract][Full Text] [Related]
15. Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype.
Ideno N; Ohtsuka T; Kono H; Fujiwara K; Oda Y; Aishima S; Ito T; Ishigami K; Tokunaga S; Ohuchida K; Takahata S; Nakamura M; Mizumoto K; Tanaka M
Ann Surg; 2013 Jul; 258(1):141-51. PubMed ID: 23532108
[TBL] [Abstract][Full Text] [Related]
16. Molecular biomarkers for progression of intraductal papillary mucinous neoplasm of the pancreas.
Kuboki Y; Shimizu K; Hatori T; Yamamoto M; Shibata N; Shiratori K; Furukawa T
Pancreas; 2015 Mar; 44(2):227-35. PubMed ID: 25423558
[TBL] [Abstract][Full Text] [Related]
17. GNAS mutation is a frequent event in pancreatic intraductal papillary mucinous neoplasms and associated adenocarcinomas.
Hosoda W; Sasaki E; Murakami Y; Yamao K; Shimizu Y; Yatabe Y
Virchows Arch; 2015 Jun; 466(6):665-74. PubMed ID: 25796395
[TBL] [Abstract][Full Text] [Related]
18. Value of adding GNAS testing to pancreatic cyst fluid KRAS and carcinoembryonic antigen analysis for the diagnosis of intraductal papillary mucinous neoplasms.
Kadayifci A; Atar M; Wang JL; Forcione DG; Casey BW; Pitman MB; Brugge WR
Dig Endosc; 2017 Jan; 29(1):111-117. PubMed ID: 27514845
[TBL] [Abstract][Full Text] [Related]
19. Next-generation sequencing of endoscopic ultrasound guided microbiopsies from pancreatic cystic neoplasms.
Vestrup Rift C; Melchior LC; Kovacevic B; Toxvaerd A; Klausen P; Karstensen JG; Kalaitzakis E; Storkholm J; Palnaes Hansen C; Vilmann P; Preuss Hasselby J
Histopathology; 2019 Nov; 75(5):767-771. PubMed ID: 31278869
[TBL] [Abstract][Full Text] [Related]
20. GNAS mutation detection in circulating cell-free DNA is a specific predictor for intraductal papillary mucinous neoplasms of the pancreas, especially for intestinal subtype.
Hata T; Mizuma M; Motoi F; Omori Y; Ishida M; Nakagawa K; Hayashi H; Morikawa T; Kamei T; Furukawa T; Unno M
Sci Rep; 2020 Oct; 10(1):17761. PubMed ID: 33082481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
